Hemophilia Tests for Women: Finding the Right Tools

The best diagnostic tools for hemophilia in women are a detailed bleeding and family history, clotting screening tests, factor VIII and factor IX activity assays, and—when appropriate—genetic testing. Because women and girls may have clinically important low factor levels even when described as carriers, assessment should be individualized by a hematologist or bleeding-disorders team.

Overview: Choosing the Right Tests

The best diagnostic tools for hemophilia in women combine clinical assessment with targeted blood tests. A clinician first considers bleeding symptoms, menstrual history, medicines and family history. Laboratory evaluation then usually includes screening clotting tests and measurement of the relevant clotting factors: factor VIII for hemophilia A and factor IX for hemophilia B.

There is no single test that is best for every person. Factor activity assays are essential for establishing whether factor levels are reduced, while genetic testing can identify a change in the F8 or F9 gene and may be particularly informative for relatives of a person with known hemophilia. Results should be interpreted by a hematologist because factor levels can vary with age, pregnancy, hormonal treatment, inflammation and other health factors.

Hemophilia is an inherited bleeding disorder in which blood does not clot normally because of too little or poorly functioning clotting factor. Hemophilia A involves factor VIII and hemophilia B involves factor IX. Both conditions can range from mild to severe, and care plans are based on symptoms, factor level and individual circumstances.

How Rare Is Hemophilia in Females?

Hemophilia is much less commonly diagnosed in females than in males because the F8 and F9 genes are located on the X chromosome. Males have one X chromosome, so an altered copy of one of these genes usually causes hemophilia. Females generally have two X chromosomes, and a second unaffected copy may provide enough clotting factor for normal or near-normal clotting.

However, females are not simply unaffected carriers. Some have reduced factor VIII or IX levels and bleeding symptoms, including heavy menstrual bleeding, prolonged bleeding after dental work, easy bruising, frequent nosebleeds or bleeding after surgery. A smaller number have hemophilia with clearly low factor levels. This can occur through inheritance from an affected father and a carrier mother, certain chromosome patterns, or uneven X-chromosome inactivation.

For this reason, experts increasingly recommend evaluating women and girls with a known family history or significant bleeding symptoms rather than assuming their status from sex alone. A normal result in one test does not always settle the question, particularly when the result was obtained during pregnancy, while using estrogen-containing treatment or during an illness that may raise factor VIII levels.

What Are the Available Methods Used to Diagnose or Test for Haemophilia?

Testing for haemophilia generally starts with a medical review and focused bleeding history. The clinician may ask about heavy or prolonged periods, postpartum bleeding, bleeding after tooth extraction or operations, large bruises, joint or muscle bleeding, and whether close relatives have hemophilia or unexplained bleeding. A structured bleeding assessment tool may help document symptoms consistently.

Blood-based testing is the main diagnostic approach. Initial screening often includes a complete blood count, prothrombin time (PT) and activated partial thromboplastin time (aPTT). If the history or screening results raise concern, the next step is specific factor testing. Factor VIII and factor IX activity assays determine whether either factor is low and help classify severity.

Additional testing may be needed to distinguish inherited hemophilia from other causes of low factor levels. A mixing study can help identify whether prolonged aPTT is caused by a factor deficiency or an inhibitor that interferes with clotting. Tests for von Willebrand disease may also be appropriate, as this common inherited bleeding disorder can lower factor VIII and cause symptoms that overlap with mild hemophilia A.

Genetic testing looks for a disease-causing variant in the F8 or F9 gene. It is useful for confirming a familial diagnosis, clarifying carrier status and informing reproductive discussions. Genetic counseling can help a person understand what a result may mean for them and their relatives.

What Lab Tests Are Used to Diagnose Hemophilia A?

The key laboratory test for hemophilia A is a factor VIII activity assay. A reduced factor VIII activity level, together with the clinical picture and appropriate exclusion of other causes, supports the diagnosis. The degree of reduction helps clinicians describe hemophilia as mild, moderate or severe and guides planning for bleeding prevention and treatment.

An aPTT may be prolonged in people with lower factor VIII levels, especially in moderate or severe hemophilia A. However, a normal aPTT does not rule out mild hemophilia A or a clinically relevant reduction in factor VIII. Therefore, people with a suggestive history should have a factor VIII assay even if a screening result is normal.

Von Willebrand factor antigen and activity tests are often ordered alongside factor VIII testing. Von Willebrand factor helps carry and stabilize factor VIII in the bloodstream, so low von Willebrand factor can reduce factor VIII levels. This evaluation helps distinguish hemophilia A from von Willebrand disease and other bleeding conditions.

If factor VIII is low, a laboratory may perform a factor VIII inhibitor test, particularly when there is unexpected bleeding, a poor response to factor replacement or no family history. Molecular testing of the F8 gene may then confirm inherited hemophilia A and identify the specific familial variant.

What Are the Screening Tests Used to Diagnose Hemophilia?

Screening tests are useful first steps, but they do not diagnose hemophilia by themselves. A complete blood count checks platelet numbers and may identify anemia caused by ongoing blood loss, such as heavy menstrual bleeding. Platelet counts are usually normal in hemophilia, but this test helps identify other possible explanations for bleeding.

The most commonly used clotting screens are PT and aPTT. PT assesses part of the clotting system that is typically normal in hemophilia A and B. The aPTT assesses a pathway that includes factors VIII and IX, so it may be prolonged when these factors are substantially reduced. Results may still be normal in mild disease.

If aPTT is prolonged, a mixing study may be performed. The laboratory mixes the person’s plasma with normal plasma and repeats the test. Correction may suggest a clotting-factor deficiency, while failure to correct can suggest an inhibitor or another interfering substance. Specific factor assays are still required to identify the exact cause.

• Complete blood count: evaluates anemia and platelet count.
• PT: usually normal in hemophilia A and B.
• aPTT: may be prolonged, but can be normal in mild hemophilia.
• Mixing study: helps distinguish a factor deficiency from an inhibitor.
• Factor VIII and IX assays: confirm and characterize hemophilia.

Interpreting Results Safely in Women

Factor levels should be interpreted in context. Factor VIII can rise during pregnancy, inflammation, stress and use of estrogen-containing medicines. This may temporarily mask a baseline reduction. Testing may therefore need to be repeated at another time, particularly when the bleeding history remains strongly suggestive.

Blood group can also influence von Willebrand factor and factor VIII levels, and laboratory methods may differ slightly between centers. A hematologist may repeat assays, use more than one assay method or request specialist coagulation testing when results are borderline or inconsistent with symptoms.

Women known to carry an F8 or F9 variant should ideally have factor levels checked before major surgery, dental extraction, invasive testing, childbirth or regional anesthesia. Obstetric and hematology teams can then make a plan to reduce bleeding risks around delivery and during the postpartum period, when factor VIII levels may fall back toward baseline.

Management may include observation and planning for procedures, medicines that support clotting in selected situations, or clotting-factor replacement when indicated. The appropriate approach depends on the diagnosis, factor level, type of bleeding and medical history. It should always be individualized by a qualified clinician.

When to Seek Medical Care

Medical assessment is advisable for women or girls with heavy periods that interfere with daily life, bleeding lasting longer than expected after a procedure, repeated large bruises without a clear cause, frequent nosebleeds, or a family history of hemophilia. It is particularly important to arrange testing before planned surgery, dental extraction, pregnancy or delivery if there is a known family history of a bleeding disorder.

Urgent medical care is needed for bleeding that does not stop with firm pressure, a significant injury followed by worsening pain or swelling, blood in urine or stool, vomiting blood, sudden severe headache, or symptoms of major blood loss such as fainting, chest discomfort or marked shortness of breath. Emergency clinicians should be told about any known hemophilia diagnosis, low factor level or family history.

For non-urgent concerns, a primary care clinician, gynecologist or hematologist can coordinate an evaluation. Acıbadem Health Point’s multidisciplinary specialists and JCI-accredited hospitals support diagnosis and care planning for international patients with suspected or confirmed bleeding disorders.

Frequently asked questions